David Lane

Q: What Schools Are Affiliated With David Lane

David Lane is affiliated with the following schools: University of Oxford, University College London, University of Dundee, Karolinska Institute, University of Cambridge

David Lane 's AcademicInfluence.com Rankings

David Lane

Medical

#272

World Rank

#402

Historical Rank

Oncology

World Rank

Historical Rank

medical Degrees

David Lane

Philosophy

#1767

World Rank

#3148

Historical Rank

Logic

#316

World Rank

#636

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

David Lane 's Degrees

Masters Medicine University of Oxford

Why Is David Lane Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Sir David Philip Lane is a British immunologist, molecular biologist and cancer researcher. He is currently working in the Department of Microbiology, Tumor and Cell Biology at the Karolinska Institute and is Chairman of Chugai Pharmabody. He is best known for the discovery of p53, one of the most important tumour suppressor genes.

(See a Problem?)

David Lane 's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Surfing the p53 network (2000) (6492)
p53, guardian of the genome (1992) (4621)
Surfing the p 53 network (2000) (2905)
T antigen is bound to a host protein in SY40-transformed cells (1979) (2485)
p53 in health and disease (2007) (2123)
International network of cancer genome projects (2010) (1839)
Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: An index of cell proliferation with evidence of deregulated expression in some, neoplasms (1990) (1486)
Cancer. p53, guardian of the genome. (1992) (1334)
p53 mutations in colorectal cancer. (1990) (1047)
Regulation of the specific DNA binding function of p53 (1992) (934)
Awakening guardian angels: drugging the p53 pathway (2009) (857)
Differential induction of transcriptionally active p53 following UV or lonizing radiation: Defects in chromosome instability syndromes? (1993) (855)
The p53 tumour suppressor gene (1998) (837)
p53: oncogene or anti-oncogene? (1990) (804)
p53 isoforms can regulate p53 transcriptional activity. (2005) (791)
Monoclonal antibody analysis of the proliferating cell nuclear antigen (PCNA). Structural conservation and the detection of a nucleolar form. (1990) (759)
High levels of p53 protein in UV-irradiated normal human skin. (1993) (692)
Drugging the p53 pathway: understanding the route to clinical efficacy (2014) (667)
Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. (1990) (637)
p53 In tumour pathology: Can we trust immunohistochemistry?—revisited! (1994) (625)
The role of p53 in spontaneous and radiation-induced apoptosis in the gastrointestinal tract of normal and p53-deficient mice. (1994) (621)
High efficiency gene transfer into mammalian cells. (1984) (609)
Mdm2-Mediated NEDD8 Conjugation of p53 Inhibits Its Transcriptional Activity (2004) (562)
Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. (1991) (560)
An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. (1992) (551)
p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress (2006) (542)
Two Pathways for Base Excision Repair in Mammalian Cells (*) (1996) (518)
Discovery, In Vivo Activity, and Mechanism of Action of a Small-Molecule p53 Activator (2007) (497)
Small peptides activate the latent sequence-specific DNA binding function of p53 (1995) (462)
Thermodynamic stability of wild-type and mutant p53 core domain. (1997) (409)
p53 Research: the past thirty years and the next thirty years. (2010) (403)
The role of mutant p53 in human cancer (2011) (380)
Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo (1997) (375)
Translating p53 into the clinic (2010) (367)
In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R‐roscovitine) (2002) (365)
A death in the life of p53 (1993) (342)
p53 expression and prognosis in gastric carcinoma (1992) (339)
Allosteric activation of latent p53 tetramers (1994) (328)
Analysis of p53 expression in human tumours: an antibody raised against human p53 expressed in Escherichia coli. (1992) (321)
Mutations of p53 and ras genes in radon-associated lung cancer from uranium miners (1992) (320)
p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding (1997) (319)
Patterns of expression of the p53 tumour suppressor in human breast tissues and tumours in situ and in vitro (1990) (305)
A small peptide inhibitor of DNA replication defines the site of interaction between the cyclin-dependent kinase inhibitor p21WAF1 and proliferating cell nuclear antigen (1995) (298)
Tumour suppressors, kinases and clamps: How p53 regulates the cell cycle in response to DNA damage (1995) (296)
A comparison of immunohistochemical markers of cell proliferation with experimentally determined growth fraction (1991) (295)
Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1. (2005) (293)
The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot. (1992) (286)
An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo (2000) (285)
p53 isoforms Δ133p53 and p53β are endogenous regulators of replicative cellular senescence (2009) (263)
Monoclonal antibody analysis of p53 expression in normal and transformed cells (1986) (261)
Negative regulation of viral enhancers in undifferentiated embryonic stem cells (1985) (259)
Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others (2018) (258)
Transcription — guarding the genome by sensing DNA damage (2004) (256)
Localization of p53, retinoblastoma and host replication proteins at sites of viral replication in herpes-infected cells (1991) (255)
Expression of p53 in premalignant and malignant squamous epithelium. (1991) (252)
An immunoaffinity purification procedure for SV40 large T antigen. (1985) (248)
Molecular characterization of the hdm2-p53 interaction. (1997) (246)
p53 and DNA polymerase α compete for binding to SV40 T antigen (1987) (246)
Immunochemical analysis of the interaction of p53 with MDM2;--fine mapping of the MDM2 binding site on p53 using synthetic peptides. (1994) (245)
p53-based cancer therapy. (2010) (244)
The p53-mdm2 autoregulatory feedback loop: a paradigm for the regulation of growth control by p53? (1993) (242)
Molecular recognition and the future of monoclonal antibodies (1982) (240)
Coupling between gamma irradiation, p53 induction and the apoptotic response depends upon cell type in vivo. (1995) (239)
Semirational design of active tumor suppressor p53 DNA binding domain with enhanced stability. (1998) (239)
Activation of p53 in cervical carcinoma cells by small molecules. (2000) (232)
P53 abnormalities and outcomes in colorectal cancer: a systematic review (2005) (231)
The p53 response to ionising radiation in adult and developing murine tissues. (1996) (230)
p53 protein accumulates frequently in early bronchial neoplasia. (1993) (225)
p53 mutation and protein accumulation during multistage human esophageal carcinogenesis. (1992) (219)
Identification of novel mdm2 binding peptides by phage display. (1996) (204)
Abnormal expression of wild type p53 protein in normal cells of a cancer family patient (1992) (204)
Archival analysis of p53 genetic and protein alterations in Chinese esophageal cancer. (1991) (203)
Loss of chromosome 17p13 sequences and mutation of p53 in human breast carcinomas. (1991) (203)
p53 and human cancers. (1994) (203)
SV40 large T shares an antigenic determinant with a cellular protein of molecular weight 68,000 (1980) (202)
Assessment of p53 protein expression in normal, benign, and malignant oral mucosa (1992) (195)
Mutant conformation of p53. Precise epitope mapping using a filamentous phage epitope library. (1992) (195)
Activation of the cryptic DNA binding function of mutant forms of p53. (1993) (194)
Different effects of p14ARF on the levels of ubiquitinated p53 and Mdm2 in vivo (2001) (194)
Requirement for the replication protein SSB in human DMA excision repair (1991) (193)
Prognostic value of proliferating cell nuclear antigen in gastric carcinoma. (1991) (189)
Mutant p53 enhances MET trafficking and signalling to drive cell scattering and invasion (2012) (188)
Stapled peptides with improved potency and specificity that activate p53. (2013) (187)
C-terminal phosphorylation of Hsp70 and Hsp90 regulates alternate binding to co-chaperones CHIP and HOP to determine cellular protein folding/degradation balances (2013) (184)
Characterisation of epitopes on human p53 using phage-displayed peptide libraries: insights into antibody-peptide interactions. (1995) (184)
Cell type-specific responses of human cells to inhibition of replication licensing (2002) (181)
Comparative study of the p53-mdm2 and p53-MDMX interfaces (1999) (179)
Suppression of the Deubiquitinating Enzyme USP5 Causes the Accumulation of Unanchored Polyubiquitin and the Activation of p53* (2009) (177)
Origins of the prestalk-prespore pattern in Dictyostelium development (1989) (177)
Expression of mutant p53 in melanoma. (1991) (175)
Protein synthesis required to anchor a mutant p53 protein which is temperature-sensitive for nuclear transport (1991) (173)
Nuclear protein with sequence homology to translation initiation factor eIF-4A (1988) (172)
Expression of mutant p53, c-erbB-2 and the epidermal growth factor receptor in transitional cell carcinoma of the human urinary bladder. (1991) (171)
Loss of heterozygosity and mutational alterations of the p53 gene in skin tumours of interspecific hybrid mice. (1991) (169)
p53, c-erbB-2 and the epidermal growth factor receptor in the benign and malignant prostate. (1992) (168)
Chaperone-dependent stabilization and degradation of p53 mutants (2008) (166)
The relationship of p53 immunostaining to survival in carcinoma of the lung. (1992) (166)
Homologous regions of Fen1 and p21Cip1 compete for binding to the same site on PCNA: a potential mechanism to co-ordinate DNA replication and repair (1997) (164)
Structure-activity relationship of truncated and substituted analogues of the intracellular delivery vector Penetratin. (2000) (164)
Loss of function of def selectively up-regulates Delta113p53 expression to arrest expansion growth of digestive organs in zebrafish. (2005) (160)
Regulation of p53 by the Ubiquitin-conjugating Enzymes UbcH5B/C in Vivo* (2004) (158)
Hypophosphorylation of Mdm2 Augments p53 Stability (2002) (156)
Haemangiopericytomas: the prognostic value of immunohistochemical staining with a monoclonal antibody to proliferating cell nuclear antigen (PCNA) (1991) (156)
Expression of p53 protein in infiltrating and in‐situ breast carcinomas (1991) (155)
Inhibitors of cyclin-dependent kinases as anti-cancer therapeutics. (2000) (154)
Inhibition of pRb phosphorylation and cell-cycle progression by a 20-residue peptide from p16CDKN2/INK4A (1996) (153)
p53 isoform delta113p53 is a p53 target gene that antagonizes p53 apoptotic activity via BclxL activation in zebrafish. (2009) (152)
Cell-cycle arrest and inhibition of Cdk4 activity by small peptides based on the carboxy-terminal domain of p21WAF1 (1997) (149)
Molecular simulations of protein dynamics: new windows on mechanisms in biology (2008) (149)
Double-edged swords as cancer therapeutics: simultaneously targeting p53 and NF-κB pathways (2008) (148)
A novel CDK inhibitor, CYC202 (R-roscovitine), overcomes the defect in p53-dependent apoptosis in B-CLL by down-regulation of genes involved in transcription regulation and survival. (2005) (148)
Discriminating functional and non‐functional p53 in human tumours by p53 and MDM2 immunohistochemistry (2005) (146)
An inhibitor of nuclear export activates the p53 response and induces the localization of HDM2 and p53 to U1A-positive nuclear bodies associated with the PODs. (1999) (144)
The regulation of p53 function: Steiner award lecture (1994) (143)
p53 Protein alterations in human testicular cancer including pre‐invasive intratubular germ‐cell neoplasia (1991) (140)
Specific activation of the p53 pathway by low dose actinomycin D: A new route to p53 based cyclotherapy (2009) (140)
ras-Induced hyperplasia occurs with mutation of p53, but activated ras and myc together can induce carcinoma without p53 mutation (1992) (138)
Reactivation of p53: from peptides to small molecules. (2011) (136)
Therapeutic exploitation of the p53 pathway. (2002) (135)
Differential regulation of p53 and p21 by MKRN1 E3 ligase controls cell cycle arrest and apoptosis (2009) (135)
Cocompartmentalization of p53 and Mdm2 is a major determinant for Mdm2-mediated degradation of p53. (2001) (134)
MDM2--arbiter of p53's destruction. (1997) (132)
A decadally-resolved paleohurricane record archived in the late Holocene sediments of a Florida sinkhole (2011) (131)
In vitro and In vivo Pharmacokinetic-Pharmacodynamic Relationships for the Trisubstituted Aminopurine Cyclin-Dependent Kinase Inhibitors Olomoucine, Bohemine and CYC202 (2005) (129)
A role for the human single-stranded DNA binding protein HSSB/RPA in an early stage of nucleotide excision repair. (1992) (129)
Functionalised staple linkages for modulating the cellular activity of stapled peptides (2014) (123)
Structural and biochemical studies of human proliferating cell nuclear antigen complexes provide a rationale for cyclin association and inhibitor design. (2005) (123)
p68 RNA helicase: identification of a nucleolar form and cloning of related genes containing a conserved intron in yeasts (1991) (122)
Cellular delivery of impermeable effector molecules in the form of conjugates with peptides capable of mediating membrane translocation. (2001) (122)
Drugging the p53 pathway: understanding the route to clinical efficacy (2014) (121)
Novel cambinol analogs as sirtuin inhibitors: synthesis, biological evaluation, and rationalization of activity. (2009) (121)
Scotin, a novel p53-inducible proapoptotic protein located in the ER and the nuclear membrane (2002) (120)
Isolation and analysis of the fission yeast gene encoding polymerase delta accessory protein PCNA. (1992) (118)
Small Molecular Weight Variants of p53 Are Expressed in Human Melanoma Cells and Are Induced by the DNA-Damaging Agent Cisplatin (2008) (116)
p53 isoforms regulate astrocyte-mediated neuroprotection and neurodegeneration (2016) (115)
APC EXPRESSION IN NORMAL HUMAN TISSUES (1997) (114)
Clinical utility of the immunocytochemical detection of p53 protein in cytological specimens. (1994) (113)
Oxidative stress is involved in the UV activation of p53. (1996) (113)
Regulation of the cryptic sequence-specific DNA-binding function of p53 by protein kinases. (1994) (112)
EDITORIAL. p53—INTEGRATING THE COMPLEXITY (1996) (110)
Tumour suppressors: A developing role for p53? (1997) (109)
Discovery of a novel family of CDK inhibitors with the program LIDAEUS: structural basis for ligand-induced disordering of the activation loop. (2003) (108)
Immunohistochemical detection of p53 and bcl‐2 proteins in non‐Hodgkin's lymphoma (1993) (106)
The prognostic significance of the accumulation of p53 tumour-suppressor gene protein in gastric adenocarcinoma. (1994) (105)
Mutant p53 uses p63 as a molecular chaperone to alter gene expression and induce a pro-invasive secretome (2011) (105)
p53 directly transactivates Δ133p53α, regulating cell fate outcome in response to DNA damage (2011) (104)
p53 isoforms regulate aging- and tumor-associated replicative senescence in T lymphocytes. (2013) (103)
p53 tumour suppressor (1998) (100)
Overexpression of the p53 protein and allele loss at 17p13 in ovarian carcinoma. (1992) (100)
PCNA binding proteins in Drosophila melanogaster : the analysis of a conserved PCNA binding domain. (1998) (99)
A unique role for p53 in the regulation of M2 macrophage polarization (2014) (99)
Differential binding of p53 and nutlin to MDM2 and MDMX: Computational studies (2010) (99)
p53 mutant breast cancer patients expressing p53γ have as good a prognosis as wild-type p53 breast cancer patients (2011) (97)
Epithelial proliferation in Barrett's esophagus by proliferating cell nuclear antigen immunolocalization. (1992) (97)
p53 protein in odontogenic cysts: increased expression in some odontogenic keratocysts. (1992) (97)
A direct effect of activated human p53 on nuclear DNA replication. (1995) (96)
Mutant p53, EGF receptor and c-erbB-2 expression in human breast cancer. (1991) (96)
Improving cancer therapy by non-genotoxic activation of p53. (2003) (96)
p53 protein expression in benign and malignant skin tumours (1993) (94)
Regulation of p53 protein expression in human breast cancer cell lines. (1993) (93)
MdmX is a substrate for the deubiquitinating enzyme USP2a (2010) (93)
Multiple peptide conformations give rise to similar binding affinities: molecular simulations of p53-MDM2. (2008) (93)
Immunohtstochemical analysis of the p53 oncoprotein on paraffin sections using a series of novel monoclonal antibodies (1993) (92)
Rapid induction of apoptosis mediated by peptides that bind initiation factor eIF4E (2000) (92)
Strategies for manipulating the p53 pathway in the treatment of human cancer. (2000) (91)
A comparison and optimization of methods and factors affecting the transformation of Escherichia coli (2013) (91)
p53 expression in colorectal adenomas. (1993) (90)
Drug discovery and p53. (2003) (89)
Discovery and characterization of 2-anilino-4- (thiazol-5-yl)pyrimidine transcriptional CDK inhibitors as anticancer agents. (2010) (88)
A quantitative study of the in vitro binding of the C-terminal domain of p21 to PCNA: affinity, stoichiometry, and thermodynamics. (2000) (86)
Effects on normal fibroblasts and neuroblastoma cells of the activation of the p53 response by the nuclear export inhibitor leptomycin B (1999) (85)
Positive feedback between p53 and TRF2 during telomere-damage signalling and cellular senescence (2010) (85)
Proliferating cell nuclear antigen expression in non-cycling cells may be induced by growth factors in vivo. (1994) (85)
Expression of P53 protein in normal, dysplastic, and malignant gastric mucosa: An immunohistochemical study (1993) (84)
The assessment of proliferating cell nuclear antigen (PCNA) immunostaining in primary gastrointestinal lymphomas and its relationship to histological grade, S + G2 + M phase fraction (flow cytometric analysis) and prognosis (1991) (83)
Discovery of N-phenyl-4-(thiazol-5-yl)pyrimidin-2-amine aurora kinase inhibitors. (2010) (83)
Modulation of p53β and p53γ expression by regulating the alternative splicing of TP53 gene modifies cellular response (2014) (82)
Ku Selectively Transfers between DNA Molecules with Homologous Ends* (1997) (82)
Cyclin-Dependent Kinase Inhibitors Sensitize Tumor Cells to Nutlin-Induced Apoptosis: a Potent Drug Combination (2007) (80)
Mdm2 and p53 are highly conserved from placozoans to man (2010) (80)
The RNA helicase p68 (DDX5) is selectively required for the induction of p53-dependent p21 expression and cell cycle arrest after DNA damage (2012) (79)
Ubiquitin-independent degradation of p53 mediated by high-risk human papillomavirus protein E6 (2007) (78)
p53 isoform Δ113p53/Δ133p53 promotes DNA double-strand break repair to protect cell from death and senescence in response to DNA damage (2015) (77)
Conformational changes in p53 analysed using new antibodies to the core DNA binding domain of the protein. (1995) (77)
The p53 isoform, Δ133p53α, stimulates angiogenesis and tumour progression (2013) (76)
The deubiquitinating enzyme USP 2 a regulates the p 53 pathway by targeting Mdm 2 (2013) (76)
Updates on p53: modulation of p53 degradation as a therapeutic approach (2008) (74)
p53-dependent growth arrest following calcium phosphate-mediated transfection of murine fibroblasts. (1995) (74)
p53 and Rb: their cellular roles. (1994) (73)
Evaluation of an Actinomycin D/VX-680 aurora kinase inhibitor combination in p53-based cyclotherapy (2010) (71)
Emerging Varieties of Capitalism in Former State Socialist Societies (2005) (71)
Accumulating active p53 in the nucleus by inhibition of nuclear export: a novel strategy to promote the p53 tumor suppressor function. (1999) (70)
p53 expression is common in malignant mesothelioma (1992) (70)
Detection of the p53 response in zebrafish embryos using new monoclonal antibodies (2008) (70)
Characterization of human p53 antigens employing primate specific monoclonal antibodies. (1983) (69)
Hexamethylene Bisacetamide (HMBA) simultaneously targets AKT and MAPK pathway and represses NF-κB activity: Implications for cancer therapy (2008) (69)
The role of the p53 protein in the apoptotic response. (1994) (69)
Exploiting the p53 pathway for cancer diagnosis and therapy. (1999) (68)
Combination of nutlin-3 and VX-680 selectively targets p53 mutant cells with reversible effects on cells expressing wild-type p53 (2010) (68)
R-Roscovitine simultaneously targets both the p53 and NF-κB pathways and causes potentiation of apoptosis: implications in cancer therapy (2007) (68)
Inhibition of pRb phosphorylation and cell-cycle progression by a 20-residue peptide derived from p16CDKN2/INK4A. (1996) (68)
Autophagic degradation of the inhibitory p53 isoform Δ133p53α as a regulatory mechanism for p53-mediated senescence (2014) (68)
Small-molecule inhibitors of the p53 suppressor HDM2: have protein-protein interactions come of age as drug targets? (2004) (67)
Combining native and ‘omics’ mass spectrometry to identify endogenous ligands bound to membrane proteins (2020) (66)
p53 Immunohistochemistry in malignant fibrous histiocytomas and other mesenchymal tumours (1992) (65)
Nutlin-3 inhibits the NFκB Pathway in a p53 Dependent Manner: Implications in Lung Cancer Therapy (2007) (65)
Constitutional mutation in exon 8 of the p53 gene in a patient with multiple primary tumours: molecular and immunohistochemical findings. (1993) (65)
Stapled peptide design: principles and roles of computation. (2016) (64)
p14 Arf Promotes Small Ubiquitin-like Modifier Conjugation of Werners Helicase* (2004) (64)
When monoclonal antibodies are not monospecific: Hybridomas frequently express additional functional variable regions (2018) (63)
Mutant p53 interactome identifies nardilysin as a p53R273H‐specific binding partner that promotes invasion (2012) (63)
P53 in cancer: a paradigm for modern management of cancer. (2005) (63)
Epitope mapping using bacteriophage peptide libraries. (1993) (62)
Strategies for manipulating the p53 pathway in the treatment of human cancer (2000) (62)
p53 and DNA polymerase alpha compete for binding to SV40 T antigen. (1987) (62)
The p16(INK4a) tumour suppressor protein inhibits alphavbeta3 integrin-mediated cell spreading on vitronectin by blocking PKC-dependent localization of alphavbeta3 to focal contacts. (1999) (62)
Mutations in p53 are frequent in the preneoplastic stage of mouse mammary tumor development. (1993) (62)
Prognostic significance of p53 overexpression in primary breast cancer; a novel luminometric immunoassay applicable on steroid receptor cytosols. (1995) (62)
Tropical cyclone wind speed constraints from resultant storm surge deposition: A 2500 year reconstruction of hurricane activity from St. Marks, FL (2013) (61)
Structure and function of SV40 large-T antigen. (1987) (61)
Coming to terms with death: apoptosis in cancer and immune development. (1994) (61)
Phosphatase WIP1 regulates adult neurogenesis and WNT signaling during aging. (2014) (60)
Expression of the p53 tumour suppressor gene product is a determinant of chemosensitivity. (1994) (59)
Highly potent p21(WAF1)-derived peptide inhibitors of CDK-mediated pRb phosphorylation: delineation and structural insight into their interactions with cyclin A. (2002) (59)
Def defines a conserved nucleolar pathway that leads p53 to proteasome-independent degradation (2013) (58)
Metabolism and pharmacokinetics of the cyclin-dependent kinase inhibitor R-roscovitine in the mouse. (2005) (57)
p 53 mutations in colorectal cancer ( immunohistokogy / polymerase chain reaction / chemical mismatch cleavage / adenocarcinoma ) (57)
Insights into cyclin groove recognition: complex crystal structures and inhibitor design through ligand exchange. (2003) (57)
Linkage studies in a Li-Fraumeni family with increased expression of p53 protein but no germline mutation in p53. (1994) (57)
Targeting a scavenger receptor on tumor-associated macrophages activates tumor cell killing by natural killer cells (2020) (57)
A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage (2018) (56)
Radiation-induced astrocyte senescence is rescued by &Dgr;133p53 (2019) (55)
The Orange Revolution: ‘People's Revolution’ or Revolutionary Coup? (2008) (55)
Mapping the Structural and Dynamical Features of Multiple p53 DNA Binding Domains: Insights into Loop 1 Intrinsic Dynamics (2013) (55)
Structural determinants of CDK4 inhibition and design of selective ATP competitive inhibitors. (2004) (55)
Wild-type and mutant p53 mediate cisplatin resistance through interaction and inhibition of active caspase-9 (2013) (55)
Characterization of a new intrabody directed against the N-terminal region of human p53 (1998) (54)
HEXIM1 and the Control of Transcription Elongation: From Cancer and Inflammation to AIDS and Cardiac Hypertrophy (2007) (53)
The dominating effect of mutant p53 (1995) (53)
An immunochemical investigation of SV40 T antigens. 1. Production properties and specificity of rabbit antibody to purified simian virus 40 large-T antigen. (1978) (52)
Isg15 controls p53 stability and functions (2014) (52)
Rational Optimization of Conformational Effects Induced By Hydrocarbon Staples in Peptides and their Binding Interfaces (2013) (52)
Cellular localization and T antigen binding of the retinoblastoma protein. (1992) (52)
Comparison between p53 staining in tissue sections and p53 proteins levels measured by an ELISA technique. (1993) (52)
Diverse p63 and p73 isoforms regulate Δ133p53 expression through modulation of the internal TP53 promoter activity (2011) (52)
Cancer: Awakening angels (1998) (51)
Cancer. A death in the life of p53. (1993) (50)
Protein interactions at the carboxyl terminus of p53 result in the induction of its in vitro transactivation potential (1997) (50)
Nucleophosmin interacts with HEXIM1 and regulates RNA polymerase II transcription. (2008) (50)
The p53 knowledgebase: an integrated information resource for p53 research (2007) (49)
An immunocytochemical study of p53 and bcl-2 protein expression in Hodgkin's disease. (1993) (49)
What kind of capitalism for Russia?: A comparative analysis (2000) (48)
Exploiting the p53 pathway for the diagnosis and therapy of human cancer. (2005) (48)
Modulation of the p53-MDM2 Interaction by Phosphorylation of Thr18: A Computational Study (2007) (47)
On the regulation of the p53 tumour suppressor, and its role in the cellular response to DNA damage. (1995) (46)
Expression of the p53 protein in a spectrum of astrocytic tumours (1992) (46)
MDM2 SNP309 is associated with high grade node positive breast tumours and is in linkage disequilibrium with a novel MDM2 intron 1 polymorphism (2008) (46)
The p53-Mdm2 pathway: targets for the development of new anticancer therapeutics. (2003) (46)
Worrying about p53 (1992) (45)
Differences in the transactivation domains of p53 family members: a computational study (2010) (45)
Stapled peptides in the p53 pathway: Computer simulations reveal novel interactions of the staples with the target protein (2010) (45)
The effects of Antibody Engineering CH and CL in Trastuzumab and Pertuzumab recombinant models: Impact on antibody production and antigen-binding (2018) (44)
Peptidomimetic design of CDK inhibitors targeting the recruitment site of the cyclin subunit. (2003) (44)
HPV-16 E7 or adenovirus E1A can overcome the growth arrest of cells immortalized with a temperature-sensitive p53. (1993) (44)
How the Other Half Lives: What p53 Does When It Is Not Being a Transcription Factor (2019) (43)
Biological significance of a small highly conserved region in the N terminus of the p53 tumour suppressor protein. (2001) (43)
Oligomerization of the Human ARF Tumor Suppressor and Its Response to Oxidative Stress* (2003) (42)
p53--integrating the complexity. (1996) (42)
Effect of VH–VL Families in Pertuzumab and Trastuzumab Recombinant Production, Her2 and FcγIIA Binding (2018) (42)
New insights into p53 based therapy. (2011) (41)
Understanding p53 functions through p53 antibodies (2019) (41)
Inhibition of cell proliferation by the PCNA-binding region of p21 expressed as a GFP miniprotein. (2001) (41)
Cassette dosing pharmacokinetics of a library of 2,6,9-trisubstituted purine cyclin-dependent kinase 2 inhibitors prepared by parallel synthesis. (2004) (40)
Tumour suppressor genes and molecular chaperones. (1993) (40)
p53 isoforms regulate premature aging in human cells (2017) (40)
Monoclonal antibody to simian virus 40 small t (1984) (40)
On the interaction mechanisms of a p53 peptide and nutlin with the MDM2 and MDMX proteins: A Brownian dynamics study (2013) (39)
Immunochemical analysis of the p53 oncoprotein in matched primary and metastatic human tumours. (1993) (39)
Turning the key on p53 (2004) (39)
p53 from pathway to therapy (2004) (39)
bioPROTACs as versatile modulators of intracellular therapeutic targets including proliferating cell nuclear antigen (PCNA) (2020) (39)
Oncogenic intelligence: Cell immortalization and transformation by the p53 gene (1984) (38)
Benzene Probes in Molecular Dynamics Simulations Reveal Novel Binding Sites for Ligand Design (2016) (38)
Identification of a putative RNA helicase in E.coli. (1990) (38)
Proliferating cell nuclear antigen immunolocalization in gastro-intestinal epithelia. (1991) (38)
Modulation of p53 binding to MDM2: computational studies reveal important roles of Tyr100 (2009) (38)
Molecular events including p53 and k-ras alterations in the in vitro progression of a human colorectal adenoma cell line to an adenocarcinoma. (1993) (37)
Macrocyclic α helical peptide therapeutic modality: A perspective of learnings and challenges. (2018) (37)
Targeting ATM pathway for therapeutic intervention in cancer (2012) (37)
Stapled BH3 Peptides against MCL-1: Mechanism and Design Using Atomistic Simulations (2012) (37)
Exploiting the p53 Pathway for Therapy. (2017) (36)
Expression of p53 protein in invasive colorectal carcinomas of different histologic types (1992) (36)
The N terminus of the murine p53 tumour suppressor is an independent regulatory domain affecting activation and thermostability. (1998) (36)
Mdm2 in evolution. (2012) (36)
Investigating peptide sequence variations for 'double-click' stapled p53 peptides. (2014) (36)
Assessing the Efficacy of Mdm2/Mdm4-Inhibiting Stapled Peptides Using Cellular Thermal Shift Assays (2015) (35)
Rapid colorimetric detection of p53 protein function using DNA-gold nanoconjugates with applications for drug discovery and cancer diagnostics. (2018) (35)
Influenza A Viruses Control Expression of Proviral Human p53 Isoforms p53β and Δ133p53α (2012) (35)
Regulation of the p14ARF promoter by DNA methylation (2008) (34)
Ionizing radiation induces a dramatic persistence of p53 protein accumulation and DNA damage signaling in mutant p53 zebrafish (2013) (34)
The role of TP53 in breast cancer development. (1993) (33)
Mutational spectra and immunohistochemical analyses of p53 in human cancers. (1992) (33)
Simulations of mutant p53 DNA binding domains reveal a novel druggable pocket (2019) (33)
Epitope analysis of the murine p53 tumour suppressor protein. (1996) (33)
Dominant nonresponsiveness in the induction of autoimmunity to liver- specific F antigen (1975) (33)
Conservation of all three p53 family members and Mdm2 and Mdm4 in the cartilaginous fish (2011) (33)
The p53 isoforms are differentially modified by Mdm2 (2012) (33)
The p53–Mdm2 interaction and the E3 ligase activity of Mdm2/Mdm4 are conserved from lampreys to humans (2016) (33)
The Fluorescent Two-Hybrid Assay to Screen for Protein–Protein Interaction Inhibitors in Live Cells (2014) (33)
High Mdm4 levels suppress p53 activity and enhance its half-life in acute myeloid leukaemia (2013) (32)
Design of a novel MDM2 binding peptide based on the p53 family (2009) (32)
p53 expression in dyskeratosis congenita: a marker for oral premalignancy? (1993) (32)
Enlarged family of putative helicases (1988) (32)
Using the polymerase chain reaction to modify expression plasmids for epitope mapping. (1989) (31)
Crystallization of eIF4E complexed with eIF4GI peptide and glycerol reveals distinct structural differences around the cap-binding site (2009) (31)
The p53 inducing drug dosage may determine quiescence or senescence (2010) (31)
A yeast two-hybrid system for the screening and characterization of small-molecule inhibitors of protein–protein interactions identifies a novel putative Mdm2-binding site in p53 (2017) (31)
Flow cytometric characterisation of proliferating cell nuclear antigen using the monoclonal antibody PC10. (1992) (30)
In Vitro Selection of Mutant HDM2 Resistant to Nutlin Inhibition (2013) (30)
A Patient-Derived Cell Atlas Informs Precision Targeting of Glioblastoma. (2020) (30)
A study of cell proliferation in formalin‐fixed, wax‐embedded bone marrow trephine biopsies using the monoclonal antibody PC10, reactive with proliferating cell nuclear antigen (PCNA) (1992) (30)
Rational design and biophysical characterization of thioredoxin-based aptamers: insights into peptide grafting. (2010) (30)
Monoclonal Antibodies against Specific p53 Hotspot Mutants as Potential Tools for Precision Medicine. (2018) (30)
The adenovirus Ela gene induces differentiation of F9 teratocarcinoma cells (1987) (30)
A rapid antibody assay system for screening hybridoma cultures. (1981) (30)
Chemical states of the N-terminal “lid” of MDM2 regulate p53 binding: Simulations reveal complexities of modulation (2011) (29)
Structure of a Stapled Peptide Antagonist Bound to Nutlin-Resistant Mdm2 (2014) (29)
An immunochemical investigation of SV40 T-antigens. 2. Quantitation of antigens and antibody activities. (1980) (29)
Lowp53 protein expression in salivary gland tumours compared with lung carcinomas (2005) (29)
Constitutive activation of WASp in X-linked neutropenia renders neutrophils hyperactive (2018) (29)
Absence of p53 autoantibodies in a significant proportion of breast cancer patients. (1995) (29)
Cellular proteins involved in SV40 transformation (1983) (29)
The Immunocytochemical Detection of P53 Protein In Cytological Specimens: Technical Considerations (1994) (29)
A search for synergy in the binding kinetics of Trastuzumab and Pertuzumab whole and F(ab) to Her2 (2015) (28)
The Mdm2 and p53 genes are conserved in the Arachnids (2010) (28)
Inhibition of Nutlin-Resistant HDM2 Mutants by Stapled Peptides (2013) (28)
Nutlin-3 sensitizes nasopharyngeal carcinoma cells to cisplatin-induced cytotoxicity (2015) (28)
Intratumour heterogeneity of p53 expression; causes and consequences (2019) (27)
Incorporation of Putative Helix-Breaking Amino Acids in the Design of Novel Stapled Peptides: Exploring Biophysical and Cellular Permeability Properties (2019) (27)
Monoclonal antibodies to a proenkephalin A fusion peptide synthesized in Escherichia coli recognize novel proenkephalin A precursor forms. (1988) (26)
Non-structural protein 1 of parvoviruses: homology to purine nucleotide using proteins and early proteins of papovaviruses. (1986) (26)
Characterization of the complex between SV40 large T antigen and the 53K host protein in transformed mouse cells. (1980) (26)
Interactions between SV40 T antigen and DNA polymerase alpha. (1990) (26)
The electrostatic surface of MDM2 modulates the specificity of its interaction with phosphorylated and unphosphorylated p53 peptides (2008) (26)
Differential scanning fluorimetry as secondary screening platform for small molecule inhibitors of Bcl-XL (2009) (26)
The transformation of Russia: The role of the political Élite (1996) (25)
Long range recognition and selection in IDPs: the interactions of the C-terminus of p53 (2016) (25)
Growth factor stimulation of proliferating cell nuclear antigen (PCNA) in human breast epithelium in organ culture. (1991) (25)
The promise of molecular oncology (1998) (25)
Killing tumor cells with viruses—a question of specificity (1998) (25)
Human and plant proliferating-cell nuclear antigen have a highly conserved binding site for the p53-inducible gene product p21WAF1. (1996) (25)
Enhancing Specific Disruption of Intracellular Protein Complexes by Hydrocarbon Stapled Peptides Using Lipid Based Delivery (2017) (24)
CIVIL SOCIETY IN THE OLD AND NEW MEMBER STATES (2010) (24)
Modulating the p53 pathway. (2010) (24)
Proliferating cell nuclear antigen (PCNA): expression in samples of human astrocytic gliomas (1993) (24)
Curing cancer with p53. (2004) (24)
The MDM2/MDMX-p53 Antagonist PM2 Radiosensitizes Wild-Type p53 Tumors. (2018) (24)
Anatomy of Mdm2 and Mdm4 in evolution (2017) (24)
The characterisation of p53 binding phage isolated from phage peptide display libraries. (1994) (24)
Differential expression of p53, p21waf1/cip1 and hdm2 dependent on DNA damage in Bloom's syndrome fibroblasts. (1998) (23)
A Mass‐Spectrometry‐Based Approach to Distinguish Annular and Specific Lipid Binding to Membrane Proteins (2019) (23)
Simian virus 40 large T-antigen-dependent DNA replication is activated by protein phosphatase 2A in vitro (1990) (23)
Directed evolution of p53 variants with altered DNA-binding specificities by in vitro compartmentalization. (2007) (23)
Xenopus p53 is biochemically similar to the human tumour suppressor protein p53 and is induced upon DNA damage in somatic cells. (1994) (22)
Stabilizing the eIF4G1 α-helix increases its binding affinity with eIF4E: implications for peptidomimetic design strategies. (2011) (22)
The complex between simian virus 40 T antigen and a specific host protein (1980) (22)
A generic scaffold for conversion of peptide ligands into homogenous biosensors. (2013) (22)
Cellular targets for SV40 Large T-antigen (1985) (22)
New approaches to cancer therapies (1999) (22)
The Role of p 53 in Spontaneous and Radiation-induced Apoptosis in the Gastrointestinal Tract of Normal and p 53-deficient Mice 1 (2006) (22)
Limitations of party control: The government bureaucracy in the USSR (1994) (22)
R248Q mutation—Beyond p53‐DNA binding (2015) (21)
Mutant p53 accumulates in cycling and proliferating cells in the normal tissues of p53 R172H mutant mice (2015) (21)
Socialism after communism: the new market socialism (1996) (21)
Genetics of growth arrest and cell death: key determinants of tissue homeostasis. (1994) (21)
Tumor susceptibility and apoptosis defect in a mouse strain expressing a human p53 transgene. (2006) (21)
The p53-MDM2 interaction in a cancer-prone family, and the identification of a novel therapeutic target. (1996) (21)
Mass Spectrometry Reveals the Direct Action of a Chemical Chaperone. (2018) (21)
Use of simian virus 40 large T-beta-galactosidase fusion proteins in an immunochemical analysis of simian virus 40 large T antigen (1985) (21)
Lipids Shape the Electron Acceptor-Binding Site of the Peripheral Membrane Protein Dihydroorotate Dehydrogenase (2018) (21)
On the expression of the p53 protein in human cancer (2004) (21)
Forces mediating protein–protein interactions: a computational study of p53 “approaching” MDM2 (2010) (20)
Interaction of kendomycin and semi-synthetic analogues with the anti-apoptotic protein Bcl-xl. (2008) (20)
Bortezomib Stabilizes and Activates p53 in Proliferative Compartments of both Normal and Tumor Tissues In Vivo. (2019) (19)
Using targeted transgenic reporter mice to study promoter-specific p53 transcriptional activity (2012) (19)
NanoClick: A High Throughput, Target-Agnostic Peptide Cell Permeability Assay. (2021) (19)
Rapid recruitment of p53 to DNA damage sites directs DNA repair choice and integrity (2022) (19)
Two different viral transforming proteins bind the same host tumour antigen (1982) (18)
Global Capitalism and the Transformation of State Socialism (2009) (18)
Ultrasensitive dynamic light scattering based nanobiosensor for rapid anticancer drug screening (2019) (18)
Ubiquitination of HEXIM1 by HDM2 (2009) (18)
Assessment of proliferating cell nuclear antigen expression in precursor stages of gastric carcinoma using the PC10 antibody to PCNA (1993) (18)
Detecting p53 isoforms at protein level. (2013) (18)
Transition under Eltsin: The Nomenklatura and Political Elite Circulation (1997) (18)
An immune complex assay for SV40 T antigen. (1977) (18)
Tumor-specific signaling to p53 is mimicked by Mdm2 inactivation in zebrafish: insights from mdm2 and mdm4 mutant zebrafish (2015) (18)
De-risking drug discovery of intracellular targeting peptides: screening strategies to eliminate false-positive hits (2019) (18)
A highly sensitive fluorescent light-up probe for real-time detection of the endogenous protein target and its antagonism in live cells. (2015) (17)
In vitro and In vivo Pharmacokinetic-Pharmacodynamic Relationships for the Trisubstituted Aminopurine Cyclin-Dependent Kinase Inhibitors Olomoucine , Bohemine and CYC 202 (2005) (17)
Characterization, chemical optimization and anti-tumor activity of a tubulin poison identified by a p53-based phenotypic screen (2008) (17)
Dimerization of the core domain of the p53 family: A computational study (2009) (17)
On the origin of the stereoselective affinity of Nutlin-3 geometrical isomers for the MDM2 protein (2013) (17)
Why is F19Ap53 unable to bind MDM2? Simulations suggest crack propagation modulates binding (2012) (16)
Induction of endogenous β-galactosidase by ionizing radiation complicates the analysis of p53-LacZ transgenic mice (2001) (16)
Overexpression of wild-type p53 and c-Myc in human fetal cells transformed with adenovirus early region 1. (1993) (16)
Improved eIF4E Binding Peptides by Phage Display Guided Design: Plasticity of Interacting Surfaces Yield Collective Effects (2012) (16)
Macrocyclization of an all-d linear α-helical peptide imparts cellular permeability† †Electronic supplementary information (ESI) available. See DOI: 10.1039/c9sc06383h (2020) (16)
Inhibiting p53 Acetylation Reduces Cancer Chemotoxicity. (2017) (16)
MDM4 downregulates p53 transcriptional activity and response to stress during differentiation (2011) (16)
Characterization of the Ligand Receptor Encounter Complex and Its Potential for in Silico Kinetics-Based Drug Development. (2012) (16)
Binding of Translationally Controlled Tumour Protein to the N-Terminal Domain of HDM2 Is Inhibited by Nutlin-3 (2012) (15)
Cancer: How cells choose to die (2001) (15)
Recognition Dynamics of p53 and MDM2: Implications for Peptide Design. (2016) (15)
Targeting codon 158 p53-mutant cancers via the induction of p53 acetylation (2020) (14)
Epitope Mapping of Antibodies Recognising the N-Terminal Domain of Simian Virus Large Tumour Antigen (1998) (14)
CD36 and LC3B initiated autophagy in B cells regulates the humoral immune response (2021) (14)
Avoiding drug resistance through extended drug target interfaces: a case for stapled peptides (2016) (14)
Anthony Dipple Carcinogenesis Award. p53 from pathway to therapy. (2004) (14)
Diversity of human p53 mutants revealed by complex formation to SV40 T antigen. (1992) (14)
Use of peptides from p21 (Waf1/Cip1) to investigate PCNA function in Xenopus egg extracts. (2001) (14)
NPMc+ AML cell line shows differential protein expression and lower sensitivity to DNA-damaging and p53-inducing anticancer compounds (2011) (14)
Characterizing the conformational landscape of MDM2-binding p53 peptides using Molecular Dynamics simulations (2017) (14)
Structural insights reveal a recognition feature for tailoring hydrocarbon stapled-peptides against the eukaryotic translation initiation factor 4E protein† †Electronic supplementary information (ESI) available. See DOI: 10.1039/c8sc03759k (2019) (13)
Therapeutic anti-cancer activity of antibodies targeting sulfhydryl bond constrained epitopes on unglycosylated RON receptor tyrosine kinase (2019) (13)
Overview of biological and chemical conditions on the Flemish Cap with comparisons of the Grand Banks Shelf and slope waters during 1996-2003 (2005) (13)
Expression of p53 in reactive mesothelium (1993) (13)
P53 Immunostaining As A Marker For Oral Cancer In Diagnostic Cytopathology‐Preliminary Report (1994) (13)
The Immune Response to p 53 in Breast Cancer Patients Is Directed against Immunodominant Epitopes Unrelated to the Mutational Hot Spot 1 (1992) (13)
Mdm 2 in Evolution (2012) (13)
Detecting and quantifying p53 isoforms at mRNA level in cell lines and tissues. (2013) (12)
Wetlands and low‐gradient topography are associated with longer hydrologic transit times in Precambrian Shield headwater catchments (2019) (12)
How p53 wields the scales of fate (2012) (12)
The Role of Fluorescence In Situ Hybridization Technologies in Molecular Diagnostics and Disease Management (2000) (12)
Nuclear export inhibitor leptomycin B induces the appearance of novel forms of human Mdm2 protein (2003) (12)
Scotin: A new p63 target gene expressed during epidermal differentiation (2008) (12)
Water-Bridge Mediates Recognition of mRNA Cap in eIF4E. (2016) (12)
Tumor-Targeted Delivery of the p53-Activating Peptide VIP116 with PEG-Stabilized Lipodisks (2020) (12)
Activation of p53 by scaffold-stabilised expression of Mdm2-binding peptides: visualisation of reporter gene induction at the single-cell level (2004) (12)
Identification of the RNA2 protein of Saccharomyces cerevisiae (1986) (11)
Monitoring flux in signalling pathways through measurements of 4EBP1-mediated eIF4F complex assembly (2019) (11)
Comparative analysis ofp53 protein immunoreactivity in prostatic, lung and breast carcinomas (2005) (11)
Enzyme‐linked immunosorbent assay for p53 in gastrointestinal malignancy: comparison with immunohistochemistry (1993) (11)
Chromosome mapping of the human gene encoding the 68-kDa nuclear antigen (p68) by using the polymerase chain reaction. (1989) (11)
Simultaneous measurement of p53:Mdm2 and p53:Mdm4 protein-protein interactions in whole cells using fluorescence labelled foci (2019) (11)
Phase II study of liarozole in advanced non-small cell lung cancer. (1998) (11)
Combined proinflammatory cytokine and cognate activation of invariant natural killer T cells enhances anti-DNA antibody responses (2020) (11)
Inflammation-associated genomic instability in cancer (2019) (11)
Seeking synergy in p53 transcriptional activation for cancer therapy. (2012) (11)
p53 transcriptional pathways in breast cancer: the good, the bad and the complex (2010) (11)
From state socialism to capitalism: The role of class and the world system ☆ (2006) (11)
Development of a novel multiplex in vitro binding assay to profile p53-DNA interactions (2010) (10)
Gating by tryptophan 73 exposes a cryptic pocket at the protein-binding interface of the oncogenic eIF4E protein. (2015) (10)
High intracellular stability of the spidroin N‐terminal domain in spite of abundant amyloidogenic segments revealed by in‐cell hydrogen/deuterium exchange mass spectrometry (2019) (10)
Proliferating cell nuclear antigen and S phase fraction in endometrial stromal sarcoma. (1992) (10)
Regulation of p 53 protein expression in human breast cancer cell lines (10)
Anti-c-Met antibodies recognising a temperature sensitive epitope, inhibit cell growth (2013) (10)
Mechanism of Stapled Peptide Binding to MDM2: Possible Consequences for Peptide Design. (2014) (10)
The Soviet Industrial Worker: Social Class, Education and Control. (1979) (10)
Social class as a factor in the transformation of state socialism (2005) (10)
Cellular responses to stress (1999) (10)
A spatiotemporal characterization of the effect of p53 phosphorylation on its interaction with MDM2 (2015) (10)
New developments in small molecules targeting p53 pathways in anticancer therapy (2008) (10)
The conformational change of a murine temperature-sensitive p53 protein is independent of a change in phosphorylation status. (1992) (9)
Detection of the 113p53 protein isoform: A p53-induced protein that feeds back on the p53 pathway to modulate the p53 response in zebrafish (2010) (9)
Reactivation of mutant p53: Constraints on mechanism highlighted by principal component analysis of the DNA binding domain (2016) (9)
Post-socialist regions in the world system (2016) (9)
Host proteins that bind to or mimic SV40 large T antigen: using antibodies to look at protein interactions and their significance. (1989) (9)
The Dual Interactions of p53 with MDM2 and p300: Implications for the Design of MDM2 Inhibitors (2019) (9)
Optimization of tetrahydroindazoles as inhibitors of human dihydroorotate dehydrogenase and evaluation of their activity and in vitro metabolic stability. (2020) (9)
Cell differentiation and chemotherapy influence p53 and Mdm2 immunoreactivity in human HT29 colon cancer cells grown in scid mice. (2001) (8)
Nationalism and Communism in Eastern Europe and the Soviet Union: A Basic Contradiction? (2000) (8)
Stereoisomerism of stapled peptide inhibitors of the p53-Mdm2 interaction: an assessment of synthetic strategies and activity profiles (2019) (8)
Identity Formation and Political Elites in the Post-Socialist States (2011) (8)
Functional characterization of p53 pathway components in the ancient metazoan Trichoplax adhaerens (2016) (8)
Developing new treatments for breast cancer (2004) (8)
Targeting the cell cycle (2004) (8)
The social background and political allegiance of the political elite of the Supreme Soviet of the USSR: The terminal stage, 1984 to 1991 (1994) (8)
Book Review: Dangerous Liaisons: The Marriages and Divorces of Marxism and Feminism (2015) (8)
Monoclonal antibodies to leucine enkephalin. (1983) (8)
Identification of the gene locus controlling dominant nonresponsiveness to F-antigen (1977) (8)
Defective nuclear localization of p53 protein in a Chinese hamster cell line is associated with the formation of stable cytoplasmic protein multimers in cells with gene amplification. (2000) (8)
The International Context: Russia, Ukraine and the Drift to East-West Confrontation (2016) (8)
The Stapled Peptide PM2 Stabilizes p53 Levels and Radiosensitizes Wild-Type p53 Cancer Cells (2019) (8)
Structure-activity studies of Mdm2/Mdm4-binding stapled peptides comprising non-natural amino acids (2017) (8)
Expression of Mutant p 53 in Melanoma 1 (2006) (7)
Post-Socialist States and the World Economy: The Impact of Global Economic Crisis (2016) (7)
The regulation of gene expression in murine teratocarcinoma cells. (1985) (7)
Discovery of cell active macrocyclic peptides with on-target inhibition of KRAS signaling (2021) (7)
New Functionaliized Resins for the Synthesis of Peptide Alcohols. (2020) (7)
Reactivation of mutant p 53 : constraints on mechanism highlighted by principal component analysis of the DNA binding domain (2016) (7)
Inhibition of NLRP3 inflammasome activation by cell-permeable stapled peptides (2019) (7)
The CPSU ruling elite 1981–1991: Commonalities and divisions (1995) (7)
Monoclonal antibody analysis of simian virus 40 small t-antigen expression in infected and transformed cells (1989) (7)
Synthetic 10FN3-based mono- and bivalent inhibitors of MDM2/X function (2018) (7)
Role of the N-terminal lid in regulating the interaction of phosphorylated MDMX with p53 (2017) (7)
Specific monoclonal antibodies. (1984) (6)
Exploitation of dihydroorotate dehydrogenase (DHODH) and p53 activation as therapeutic targets: A case study in polypharmacology (2020) (6)
Translating p53 into the clinic (2011) (6)
p53 in Paris, an oncogene comes of age. (1987) (6)
Six years that shook the world: perestroika—the impossible project (1994) (6)
Identification of pathways modulating vemurafenib resistance in melanoma cells via a genome-wide CRISPR/Cas9 screen (2020) (6)
A hierarchy of responsiveness and the production of nonprecipitating antibodies to F antigen (1979) (6)
Gene therapy for gastric cancer: problems and prospects. (2000) (6)
Blue-Collar Workers in Eastern Europe (1982) (6)
Author Correction: The effects of Antibody Engineering CH and CL in Trastuzumab and Pertuzumab recombinant models: Impact on antibody production and antigen-binding (2018) (6)
Transformation of State Socialism: From Communism to Chaotic Capitalism? (1999) (6)
In or out of Europe? What prospects for Ukraine? (2007) (6)
p53: updates on mechanisms, biology and therapy (II) (2019) (5)
Checkpoint policing by p53 (1992) (5)
Stress, specificity and the NEDD8 proteome (2012) (5)
CETSA interaction proteomics define specific RNA-modification pathways as key components of fluorouracil-based cancer drug cytotoxicity. (2021) (5)
Astronomers at Altitude: Mountain Geography and the Cultivation of Scientific Legitimacy (2008) (5)
The p53 family : a subject collection from Cold Spring Harbor Perspectives in biology (2010) (5)
Publisher Correction: A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage (2018) (5)
Autophagic flux blockage by accumulation of weakly basic tenovins leads to elimination of B-Raf mutant tumour cells that survive vemurafenib (2018) (5)
Evidence for allosteric effects on p53 oligomerization induced by phosphorylation (2018) (5)
Preface to molecular and cellular themes in cancer research (1999) (5)
A novel unstructured scaffold based on 4EBP1 enables the functional display of a wide range of bioactive peptides. (2010) (5)
Enhancing the therapeutic effects of in vitro targeted radionuclide therapy of 3D multicellular tumor spheroids using the novel stapled MDM2/X-p53 antagonist PM2 (2020) (5)
Russia Against the Rest. The Post-Cold War Crisis of World Order (2020) (5)
How p 53 wields the scales of fate Arrest or death ? (2012) (5)
How to lose tumor suppression (2019) (5)
Systematic mutational analysis of an ubiquitin ligase (MDM2)-binding peptide: computational studies (2011) (5)
p53: out of Africa (2016) (5)
The hot-spot p53R172H mutant promotes formation of giant spermatogonia triggered by DNA damage (2016) (5)
Inhibition of lymphocyte proliferation by murine liver-specific F antigen. (1977) (4)
Substrate Specificity of Cyclins Determined by Electrostatics (2007) (4)
159 Stapled-peptides targeting the protein-binding interface of eukaryotic Translation Initiation Factor 4E (eIF4E) protein (2015) (4)
Rigorous Computational and Experimental Investigations on MDM2/MDMX-Targeted Linear and Macrocyclic Peptides (2019) (4)
'Mind the gap'. (2002) (4)
Immunological cross-reaction between large T-antigens of SV40 and polyoma virus. (1982) (4)
Polygenic control of the immune response to F antigen (2005) (4)
Targeting a nucleolar SUMO protease for degradation: A mechanism by which ARF induces SUMO conjugation (2008) (4)
Cancer Cells Shuttle Extracellular Vesicles Containing Oncogenic Mutant p53 Proteins to the Tumor Microenvironment (2021) (4)
Author's response to reviews Title: MDM2 SNP309 is associated with high grade node positive breast tumours and is in linkage disequilibrium with a novel MDM2 intron 1 polymorphism Authors: (2008) (4)
DNA Mediated Gene Transfer: Theory and Application (1980) (4)
Characterization of Hydration Properties in Structural Ensembles of Biomolecules (2019) (4)
A general approach to protein folding using thermostable exoshells (2021) (4)
Liposome Click Membrane Permeability Assay for Identifying Permeable Peptides (2021) (4)
DNA helicase activity of SV40 large T antigen (1986) (3)
The De-coupling of National Economic Elites from Political Elites: Russia and the UK Compared (2017) (3)
Monoclonal Antibodies against Specific p53 Hotspot Mutants as Potential Tools for Precision Medicine. (2021) (3)
Labour socialization and occupational placement in Soviet education (1976) (3)
p 53 mutant breast cancer patients expressing p 53 γ have as good a prognosis as wild-type p 53 breast cancer patients (2017) (3)
Novel p53-Based Therapies: Strategies and Future Prospects (2007) (3)
Russia's Oil and Natural Gas: Bonanza or Curse? Ed. Michael Ellman. Anthem Studies in Development and Globalization. London: Anthem Press, 2006. xi, 216 pp. Notes. Index. Figures. Tables. $29.95, paper. (2008) (3)
CYC202 (R-Roscovitine) induces apoptosis in multiple myeloma cells by down regulation of Mcl-1 (2004) (3)
Asymmetric PCR-based strategy for genetic analysis of the p53 tumor suppressor gene in cell lines and tumor tissues. (1991) (3)
Late Holocene hurricane activity and climate variability in the Northeastern Gulf of Mexico (2011) (3)
Wetting of nonconserved residue‐backbones: A feature indicative of aggregation associated regions of proteins (2016) (3)
Immunohistochemical and Ultrastructural Evidence for Myelopoiesis in the Scid/scid Mouse Thymus (1999) (3)
The Novel Anti-cMet Antibody seeMet 12 Potentiates Sorafenib Therapy and Radiotherapy in a Colorectal Cancer Model (2020) (3)
Constitutive WASp activation leads to abnormal cytotoxic cells with increased response against tumors. (2021) (3)
mAb806 binding to epidermal growth factor receptor: a computational study (2015) (3)
SHON expression predicts response and relapse risk of breast cancer patients after anthracycline-based combination chemotherapy or tamoxifen treatment (2019) (3)
Site-dependent inhibition by single O6-methylguanine bases of SV40 T-antigen interactions with the viral origin of replication. (1991) (3)
Ideology and Sociology in the U. S. S. R. (1970) (3)
432 Identification of clinically relevant pharmacodynamic biomarkers in patients treated with the CDK inhibitor CYC202 (R-roscovitine) (2004) (3)
p53: updates on mechanisms, biology and therapy (I) (2019) (3)
Constitutive activation of WASp leads to abnormal cytotoxic cells with increased granzyme B and degranulation response to target cells (2021) (3)
pSEMCatR1: a procaryotic-eucaryotic shuttle vector compatible with pUR and lambda gt11 expression systems. (1987) (2)
Exploitation of dihydroorotate dehydrogenase (DHODH) and p53 activation as therapeutic targets: A case study in polypharmacology. (2020) (2)
D133P53, directly transactivated by p53, prevents p53-mediated apoptosis without inhibiting p53-mediated cell cycle arrest (2010) (2)
O6-methylguanine in the SV40 origin of replication inhibits binding but increases unwinding by viral large T antigen (1990) (2)
Exploiting the p53 pathway for cancer diagnosis and therapy. (2003) (2)
Gorbachev's political elite in the terminal stage of the USSR: A reputational analysis (1994) (2)
p53 expression in human tumours: breast, lung, colon, bladder and prostate cancer;melanoma and lymphoma. (1993) (2)
Dangerous Liaisons: The Marriages and Divorces of Marxism and Feminism by Cinzia Arruzza (prologue by Penelope Duggan). Pontypool: Merlin Press, 2013. 150pp., £12.95, ISBN 978 0850366440 (2015) (2)
p53-Mediated Radiosensitization of 177Lu-DOTATATE in Neuroblastoma Tumor Spheroids (2021) (2)
Conformational ordering of intrinsically disordered peptides for targeting translation initiation (2020) (2)
WP 1 : Cell Biology , Autopoiesis and Biological Design Patterns D 1 . 4 : Mathematical Models of Gene Expression Computing (2)
p53 Pathway and Cancer Therapy (2012) (2)
Sport under Communism: The USSR, Czechoslovakia, the G.D.R., China, Cuba (1979) (2)
Engineering an autonomous VH domain to modulate intracellular pathways and to interrogate the eIF4F complex (2022) (2)
The p53 protein detected by immunohistochemical staining is not always mutant (1993) (2)
Explorer Chemical states of the N-terminal " lid " of MDM 2 regulate p 53 binding Simulations reveal complexities of modulation (2017) (2)
The Composition of the Politburo of the CPSU: 1966 to 1991 (1994) (2)
Conformational ordering of intrinsically disordered peptides for targeting translation initiation. (2020) (1)
Building socialism: from ‘scientific’ to ‘active’ Marxism (2020) (1)
Guardian of Genome Editing. (2018) (1)
The Transformation of State Socialism in Russia (2000) (1)
TGF-ALPHA/EGF LEVELS IN BLADDER-CANCER AND THEIR RELATIONSHIP TO EGFR (1991) (1)
Tumour diagnosis (1994) (1)
The Quantification of Antibody Elements and Receptors subunit expression using qPCR: The Design of VH, VL, CH, CL, FcR subunits primers for a more holistic view of the immune system (2019) (1)
Conformation specific antagonistic high affinity antibodies to the RON receptor kinase for imaging and therapy (2022) (1)
Drug discovery and target validation in the p53 pathway (2009) (1)
Transformative politics: the future of socialism in western Europe (1996) (1)
Can Glycosylation Mask the Detection of MHC Expressing p53 Peptides by T Cell Receptors? (2021) (1)
The Resource Curse in a Post-Communist Regime: Russia in Comparative Perspective. By Younkyoo Kim. Aldershot, Eng.: Ashgate, 2003. xiv, 181 pp. Appendixes. Notes. Bibliography. Index. Figures. Tables. $84.95, hard bound. (2005) (1)
Comment on Marshall (1996) (1)
EXPRESSION OF P53, C-ERBB-2 AND THE EPIDERMAL GROWTH-FACTOR RECEPTOR IN TRANSITIONAL CELL CARCINOMAS OF THE BLADDER (1991) (1)
Social Change and Stratification in Eastern Europe: An Interpretative Analysis of Poland and Her Neighbors (1976) (1)
Development of CDK inhibitors as cancer therapeutics (2005) (1)
Social structure and the left – right divide: The socio-economic background of voting in the first russian parliament (2006) (1)
The quantification of antibody elements and receptors subunit expression using qPCR: The design of VH, VL, CH, CL, FcR subunits primers for a more holistic view of the immune system. (2019) (1)
Assessing the Efficacy of Mdm 2 / Mdm 4-Inhibiting Stapled Peptides Using Cellular Thermal Shift Assays Ban (2017) (1)
Engineering Disulphide-Free Autonomous Antibody VH Domains to modulate intracellular pathways (2021) (1)
Transcription Factors as Detection and Diagnostic Biomarkers in Cancer (2017) (1)
Expression ofmutantp53, c-erbB-2 andtheepidermal growth factor receptor intransitional cell carcinoma ofthehumanurinary bladder (1991) (1)
Drug discovery in the p53 pathway (2000) (1)
Social democracy in a post-communist Europe (1995) (1)
The expression of p53 tumor-suppressor protein during progression of gastric and colorectal carcinomas. (1995) (1)
p53 Family Pathway in Cancer (2007) (1)
The Causes of Structural Unemployment: Four Factors that Keep People from the Jobs They Deserve by Thomas Janoski , David Luke and Christopher Oliver . Cambridge : Polity Press , 2014 . 224pp., £15.99, ISBN 978 0 7456 7028 7 (2015) (1)
Biological Oceanographic Conditions in NAFO Subareas 2 and 3 on the Newfoundland and Labrador Shelf During 2002 (2003) (1)
Corrigendum to ‘Understanding p53 functions through p53 antibodies’ (2019) (1)
Investigating the Specificity of Monoclonal Antibodies to Protein Antigens Using β-Galactosidase Fusion Proteins (1985) (1)
422 The mode of action of CYC202 (R-roscovitine) a cyclin dependent kinase inhibitor currently in phase II clinical trials (2004) (1)
Book Review: Erik Olin Wright, Understanding Class (2017) (0)
A novel function of Mdm2 that is regulated by phosphorylation (2001) (0)
bioPROTACs as versatile modulators of intracellular therapeutic targets: Application to proliferating cell nuclear antigen (PCNA) (2019) (0)
Supporting Information Macrocyclization of an all-D linear α-helical peptide imparts cellular permeability (2020) (0)
THE P53 PATHWAY (2007) (0)
Targeting a nucleolar SUMO protease for dégradation (2008) (0)
Identification du site d'interaction de p21waf1 dans pcna (antigene nucleaire a cellules proliferatives) et ses applications therapeutiques (1995) (0)
Design-Rules for Stapled Alpha-Helical Peptides with On-Target In Vivo Activity: Application to Mdm2/X dual antagonists (2023) (0)
Abstract 2915: p53 isoforms Δ133p53 and p53β are endogenous regulators of replicative cellular senescence (2010) (0)
Book Review: Ken Livingstone, Being Red: A Politics for the Future (2017) (0)
SNPing Away at Cancer. (2010) (0)
Discussion of the Paper (1994) (0)
Book Review: Capitalism and its Alternatives (2016) (0)
HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR N-[4-(2,4-Dimethyl-thiazol-5-yl)pyrimidin-2-yl]-N'-hydroxyiminoformamide (2003) (0)
HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR [4-(2,4-Dimethyl-thiazol-5-yl)-pyrimidin-2-yl]-(4-trifluoromethyl-phenyl)-amine (2003) (0)
antigen in gastric carcinoma . Prognostic value of proliferating cell nuclear (2004) (0)
Regulating and replacing suppressor gene function with small synthetic molecules; design of an active synthetic suppressor protein (1996) (0)
Book Reviews (2009) (0)
Cheap fullerenes (1994) (0)
Crystal Structure of eIF4E in Complex with a Stapled Peptide Derivative (2013) (0)
Bright future (1991) (0)
Comparisons and significance of immunohistochemistry and cytosol p53 assay in matched breast cancer samples (1993) (0)
First in vivo study of the MDM2/X-p53 antagonist PM2 as potentiator of external radiotherapy in wt p53 cancer (2018) (0)
Cyclin A binding groove inhibitor Ace-Arg-Lys-Leu-Phe-Gly (2003) (0)
The Russian social democratic labour party in ST. Petersburg, Tver and Ashkhabad, 1903–1905 (1964) (0)
Political Culture and Soviet Politics (1980) (0)
131 POSTER Specific induction of the p53 pathways by low dose cytotoxic drugs assessed by gene expression pattern analysis (2008) (0)
Regulation of p53 protein expression in human cancer (1994) (0)
Fragmented Space in the Russian Federation. Eds. Blair A. Ruble, Jodi Koehn, and Nancy E. Popson. Washington, D.C.: Woodrow Wilson Center Press and Johns Hopkins University Press, 2001. xiii, 339 pp. Notes. Index. Figures. Tables. Maps. $48.00, hard bound. (2003) (0)
APO STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2 (2003) (0)
Book Review: Russell Brand, Revolution (2016) (0)
Reviews (2010) (0)
Abstract 3199: p53 represses TRF2 through E3 ubiquitin ligase Siah-1: Feedback regulation in telomere-initiated damage signaling (2010) (0)
Book Review: General Politics: The Causes of Structural Unemployment: Four Factors that Keep People from the Jobs They Deserve (2015) (0)
Cyclin A binding groove inhibitor H-Ala-Ala-Abu-arg-er-Leu-Ile-(p-F-Phe)-NH2 (2003) (0)
Targeting codon 158 p53-mutant cancers via the induction of p53 acetylation (2020) (0)
A “spindle and thread”-mechanism unblocks translation of N-terminally disordered proteins (2021) (0)
Domain-specific p53 mutants activate EGFR by distinct mechanisms exposing tissue-independent therapeutic vulnerabilities (2023) (0)
Structure of the stapled peptide YS-02 bound to MDM2 (2016) (0)
Abstract 1312: Oncogenic mutant p53 proteins are selectively shuttled by cancer extracellular vesicles toeducate the tumor microenvironment (2023) (0)
Cyclin A binding groove inhibitor H-Arg-Arg-Leu-Ile-Phe-NH2 (2003) (0)
Monitoring flux in signalling pathways through measurements of 4EBP1-mediated eIF4F complex assembly (2019) (0)
Targeting the Interaction of p 53 with Mdm 2 and Mdm 4 Protein Interaction Inhibitors in Live Cells : − The Fluorescent Two-Hybrid Assay to Screen for Protein (2014) (0)
Characterizing the conformational landscape of MDM2-binding p53 peptides using Molecular Dynamics simulations (2017) (0)
Correction to: Liposome Click Membrane Permeability Assay for Identifying Permeable Peptides (2021) (0)
A yeast two-hybrid system for the screening and characterization of small-molecule inhibitors of protein–protein interactions identifies a novel putative Mdm2-binding site in p53 (2017) (0)
Abstract 1231: Live cell and in vitro analysis of p53 interactions (2015) (0)
Crystallization of eIF4E complexed with eIF4GI peptide and glycerol reveals distinct structural differences around the cap-binding site (2010) (0)
Correction to: Identification of pathways modulating vemurafenib resistance in melanoma cells via a genome-wide CRISPR/Cas9 screen (2022) (0)
Enhanced antigen detection in immunohistochemical staining using a 'digitized' chimeric antibody. (2015) (0)
Proteasome inhibitor bortezomib stabilizes and activates p53 in hematopoietic stem/progenitors and double-negative T cells in vivo. (2023) (0)
Inhibition of NLRP3 inflammasome activation by cell-permeable stapled peptides (2019) (0)
Picomolar Binding Selective Human Ron Inhibitory Antibodies Directed to Surface Displayed Conformational Epitopes for Imaging and Therapy (2020) (0)
SHON expression predicts response and relapse risk of breast cancer patients after anthracycline-based combination chemotherapy or tamoxifen treatment (2019) (0)
In vitro Study of the p53 Pathway in Peripheral Blood Mononuclear Cells in Response to Doxorubicin Treatment (2003) (0)
Author Correction: The effects of Antibody Engineering CH and CL in Trastuzumab and Pertuzumab recombinant models: Impact on antibody production and antigen-binding (2018) (0)
Proliferating cellnuclear antigen expression innon-cycling cells maybe induced bygrowth factors invivo (1994) (0)
Book Review: Chris Hedges, Wages of Rebellion: The Moral Imperatives of Revolt (2016) (0)
1 Drug discovery in the p53 pathway (2009) (0)
Expression of Mutant p 53 in Melanoma Updated (2006) (0)
Expression of Mutant p53 in Melanoma1 (2006) (0)
Abstract IA10: How the p53 pathway controls the response to chemotherapy (2011) (0)
9 Studying the p53 pathway using Zebra fish models (2010) (0)
Enhancing Specific Disruption of Intracellular Protein Complexes by Hydrocarbon Stapled Peptides Using Lipid Based Delivery (2017) (0)
Abstract A79: Inhibition of p53-MDM2 protein interaction reduces tumor growth in a mouse melanoma model (2020) (0)
A manual for all seasons (1991) (0)
Cyclin-Dependent Kinase Inhibitors Sensitize Tumor Cells to Nutlin-Induced Apoptosis : a Potent Drug Combination Chit (2007) (0)
Use of eIF4E-binding reagents in the therapy (2000) (0)
Complex complexes in Cambridge. The 1989 DNA Tumour Virus Meeting sponsored by the Imperial Cancer Research Fund, Churchill College Cambridge, Cambridge, UK July 24-29, 1989. (1989) (0)
Scotin expression and survival in breast cancer. (2009) (0)
Title Structure of a stapled peptide antagonist bound to nutlin-resistant Mdm 2 (2017) (0)
Title Binding of translationally controlled tumour protein to theN-terminal domain of HDM 2 is inhibited by Nutlin-3 (2017) (0)
Elites and identities in post-Soviet space (2012) (0)
Book Review: Mikhail A Molchanov, Eurasian Regionalisms and Russian Foreign Policy (2017) (0)
COMP-05. A DRUG ASSOCIATION MAP OF GLIOBLASTOMA INFORMS PRECISION TARGETING OF p53-DEPENDENT METABOLIC STATES (2019) (0)
P53 Protein and antibodies to p53 in primary brain tumors. Results from a newly developed luminometric assay for p53 compared to immuno-histochemistry (1993) (0)
Improved eIF4E binding peptides by phage display guided design. (2012) (0)
Enhancing the effect of radiotherapy in cultured tumour cells using p53 therapy (2015) (0)
Such an obsession (2006) (0)
Structure of the stapled peptide YS-01 bound to MDM2 (2016) (0)
41 Applications of the inhibition of Mdm2 function in Cancer Therapy (2010) (0)
State and Society in Post-Socialist Economies. Studies in Central and East European Europe by John Pickles (review) (2022) (0)
Book Review: Peter Hain, Back to the Future of Socialism (2017) (0)
Theprognostic significance oftheaccumulation ofp53tumour-suppressor geneprotein ingastric adenocarcinoma (1994) (0)
Enhancing therapeutic effects of radio-immunotherapy using the novel stapled MDM2/X-p53 antagonist PM2 (2018) (0)
INTERRUPTION DE LA LIAISON DE LA PROTEINE MDM2 ET p53 ET SON APPLICATION THERAPEUTIQUE (1995) (0)
Covalent Rescue of Mutant p53. (2023) (0)
NATIVE HUMAN PCNA (2005) (0)
Popular Support for an Undemocratic Regime. The Changing Views of Russians (2012) (0)
The effects of Antibody Engineering CH and CL in Trastuzumab and Pertuzumab recombinant models: Impact on antibody production and antigen-binding (2018) (0)
Correction to: Liposome Click Membrane Permeability Assay for Identifying Permeable Peptides (2021) (0)
Book Review: Benjamin Birkinbine, Rodrigo Gomez and Janet Wasko (eds), Global Media Giants (2017) (0)
Book Review: Mark Bassin, Sergey Glebov and Marlene Laruelle, Between Europe and Asia: The Origins, Theories and Legacies of Russian Eurasianism (2016) (0)
INTERRUPTION OF TYING PROTEINS MDM2 AND p53 AND RELATED THERAPEUTIC APPLICATIONS (1995) (0)
CRISPR enriches for cells with mutations in a p53-related interactome, and this can be inhibited (2021) (0)
Macrocyclization of an all-D linear peptide improves target affinity and imparts cellular activity: A novel stapled α-helical peptide modality (2019) (0)
Explorer A direct effect of activated human p 53 on nuclear DNA replication (2017) (0)
Stabilization of p53 in response to DNA damage (2001) (0)
Regulation of p53 stability. The role of Mdm2 and nuclear export (1999) (0)
231 INVITED Activation of p53 by small molecules from fish to man (2006) (0)
Abstract PR08: Autophagic degradation of Δ133p53 during replicative cellular senescence: An isoform-specific protein degradation mechanism for p53 (2013) (0)
Cyclin A binding groove inhibitor Ac-Arg-Arg-Leu-Asn-(m-Cl-Phe)-NH2 (2003) (0)
Reviews (2011) (0)
Rapid separation of isomeric perfluoro alkyl substances by high-resolution differential ion mobility mass spectrometry (2019) (0)
The Bureaucratic Leviathan: A Study in the Sociology of Communism (1981) (0)
Anti-microbial agents and screening process to (1994) (0)
New thinking in Soviet politics (1992) (0)
Dynamics of Aggregating Mutants of the P53 DNA Binding Domain Reveal A Novel “Druggable” Pocket (2016) (0)
Radioiodination Of Small Stapled Peptides For p53 Therapy (2017) (0)
Democracy Derailed in Russia: The Failure of Open Politics. By M. Steven Fish. Cambridge Studies in Comparative Politics. New York: Cambridge University Press, 2005. xvii, 313 pp. Notes. Bibliography. Index. Figures. Tables. $75.00, hard bound. $29.99, paper. (2006) (0)
Structural and biochemical studies of human PCNA complexes provide the basis for association with CDK/cyclin and a rationale for inhibitor design (2004) (0)
MDM2 inhibitors, nutlin-3a and navtemadelin, retain efficacy in human and mouse cancer cells cultured in hypoxia (2022) (0)
Water-Bridge Mediates Re cognition of mRNA Cap in eIF 4 E Graphical (2016) (0)
Title In vitro selection of mutant HDM 2 resistant to nutlininhibition (2017) (0)
Book reviews: 12 (2004) (0)
conditional expression with the tet system strategy to achieve tightly controlled in vivo Targeted transgenesis at the HPRT locus: an efficient (2015) (0)
Cover Feature: Functionalized Resins for the Synthesis of Peptide Alcohols (Chem. Eur. J. 2/2020) (2020) (0)
Activation of the p53 protein (1993) (0)
Abstract 5386: Disrupting p53:Mdm2 and p53:Mdm4 - Comparative cell-based assays for drug screening (2014) (0)
P53 protein activation. (1993) (0)
Substance se fixant a l'antigene nucleaire des cellules proliferatives (1996) (0)
HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 4-(2,5-Dichloro-thiophen-3-yl)-pyrimidin-2-ylamine (2003) (0)
In Vivo Assessment of p53 Therapy as a Way of Enhancing Therapeutic Effects of Radiation (2017) (0)
Dealing with genes: The language of heredity: by Paul Berg and Maxine Singer Blackwell Scientific, 1992. £17.95 hbk (269 pages) ISBN 0 632 03339 8 (1994) (0)
Drugs targeting p53 regulatory mechanisms (2001) (0)
NUCLEAR PROENKEPHALIN INDUCES CELL DEATH IN A P53 DOSE-DEPENDENT MANNER (1996) (0)
Crystal Structure of eIF4E Bound to Glycerol and eIF4G1 peptide (2010) (0)
A novel function of Mdm2 for p53 degradation that is regulated by phosphorylation (2001) (0)
Novel Mdm2 intron 1 single nucleotide polymorphisms and their role in breast cancer (2007) (0)
The Return of the Left in Post-Communist States: Current Trends and Future Prospects. Ed. Charles Bukowski and Barnabas Racz. Studies of Communism in Transition. Northampton, Mass.: Edward Elgar, 1999. xiii, 169 pp. Notes. Index. Tables. Maps. $70.00, hard bound (2001) (0)
Abstract B1: p53 isoforms, Δ133p53 and p53β, regulate aging-associated T lymphocyte senescence. (2011) (0)

This paper list is powered by the following services:

Other Resources About David Lane

What Schools Are Affiliated With David Lane ?

David Lane is affiliated with the following schools:

David Lane 's Academic­Influence.com Rankings

David Lane 's Degrees

Why Is David Lane Influential?

David Lane 's Published Works

Published Works

Other Resources About David Lane

What Schools Are Affiliated With David Lane ?

David Lane 's AcademicInfluence.com Rankings